Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.6x - 5.0x | 4.8x |
| Historical Pb Multiple | 0.6x - 5.6x | 3.4x |
| Fair Value | €3.16 - €3.49 | €3.33 |
| Upside | -40.3% - -34.1% | -37.2% |
| Benchmarks | - | Full Ticker |
| Grifols, S.A. | - | OTCPK:GIFL.F |
| 89bio, Inc. | - | NasdaqGM:ETNB |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Abeona Therapeutics Inc. | - | DB:PCJ |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| GIFL.F | ETNB | DYAI | ONCO | CRDF | PCJ | |||
| OTCPK:GIFL.F | NasdaqGM:ETNB | NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | DB:PCJ | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | -24.2% | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | -6.0% | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 100.1% | -157.8% | 25.8% | -25.9% | -24.9% | 42.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 5.7% | NA | -386.3% | -13605.6% | -7820.9% | -1702.6% | ||
| Prior Fiscal Year | 0.6% | NA | -234.4% | -63986.5% | -8496.9% | -1548.2% | ||
| Latest Fiscal Year | 2.2% | NA | -166.2% | -2333.4% | -6655.2% | NA | ||
| Latest Twelve Months | 4.0% | NA | -163.9% | -2986.3% | -9365.7% | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 4.5% | -55.9% | -73.9% | -395.0% | -46.8% | -178.7% | ||
| Prior Fiscal Year | 0.7% | -41.3% | -80.1% | -334.2% | -47.1% | -260.6% | ||
| Latest Twelve Months | 5.5% | -86.9% | -214.3% | -2879.9% | -92.0% | -213.5% | ||
| Next Fiscal Year | 9.2% | -134.4% | 677.6% | 222.3% | -103.0% | -257.3% | ||
| Two Fiscal Years Forward | 11.1% | 343.1% | 73.6% | 80.6% | 1098.6% | 115.7% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.0x | NA | 8.7x | 0.8x | 296.6x | NA | ||
| Price / LTM EPS | 25.9x | -3.0x | -5.3x | 0.0x | -3.2x | -7.3x | ||
| Price / Book | 1.5x | 2.6x | 33.3x | 0.4x | 2.8x | 7.8x | ||
| Price / Fwd Book | 0.9x | 17.4x | -6.8x | 0.0x | 6.1x | -57.3x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.4x | 2.6x | 33.3x | |||||
| Historical P/B Ratio | 0.6x | 3.4x | 5.6x | |||||
| Selected P/B Multiple | 4.6x | 4.8x | 5.0x | |||||
| (x) Book Value | 41 | 41 | 41 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GIFL.F | ETNB | DYAI | ONCO | CRDF | PCJ | |
| Value of Common Equity | 5,815 | 1,341 | 31 | 2 | 162 | 316 | |
| (/) Shares Outstanding | 494.6 | 148.3 | 36.2 | 0.5 | 66.5 | 51.2 | |
| Implied Stock Price | 11.76 | 9.04 | 0.85 | 2.96 | 2.43 | 6.19 | |
| FX Conversion Rate to Trading Currency | 0.86 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 13.73 | 9.04 | 0.85 | 2.96 | 2.43 | 5.30 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 0.86 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |